Stockscreener 앱 받기
34.02
10.69%
-4.07
전일 마감가:
$38.09
열려 있는:
$35.55
하루 거래량:
5.05M
Relative Volume:
2.50
시가총액:
$7.01B
수익:
$2.09B
순이익/손실:
$424.88M
주가수익비율:
16.64
EPS:
2.0439
순현금흐름:
$447.20M
1주 성능:
-15.16%
1개월 성능:
-12.93%
6개월 성능:
-29.05%
1년 성능:
-19.90%
1일 변동 폭
$33.78
$35.58
1주일 범위
$33.78
$40.42
52주 변동 폭
$33.78
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
34.02 | 7.85B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
471.99 | 173.93B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.41 | 127.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
569.07 | 45.67B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.60 | 32.67B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
301.25 | 29.43B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
German Shares Slip; Qiagen Tumbles on Outlook Downgrade - marketscreener.com
Qiagen N.V. 2026 Q1ResultsEarnings Call Presentation (NYSE:QGEN) 2026-04-28 - Seeking Alpha
Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $44 - Moomoo
Qiagen Sets Date for Publication of 2025 Annual Financial Report - TipRanks
QIAGEN NV : Deutsche Bank remains its Buy rating - marketscreener.com
QIAGEN NV : Jefferies gives a Buy rating - marketscreener.com
QIAGEN NV : Barclays remains Neutral - marketscreener.com
Qiagen Trims Guidance for FY26, Warns of Lower Net Sales in Q2 - marketscreener.com
Qiagen cuts 2026 outlook on lower immigration testing demand - Investing.com UK
QIAGEN lowers 2026 outlook as QuantiFERON immigration testing drops - StreetInsider
QIAGEN (QGEN) Revises 2026 Sales Growth Outlook - GuruFocus
Qiagen (QGEN) Shares Decline Following Earnings Guidance Revisio - GuruFocus
Qiagen (NYSE:QGEN) Updates FY 2026 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Updates Q2 2026 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Releases Q1 2026 Earnings Guidance - MarketBeat
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
Qiagen cuts 2026 outlook on lower immigration testing demand By Investing.com - Investing.com Nigeria
QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS - marketscreener.com
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook - Business Wire
Qiagen gains on report it's weighing options amid takeover interest - MSN
Qiagen Sees Unusually High Options Volume (NYSE:QGEN) - MarketBeat
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen N.V. (QGEN) Stock Analysis: Exploring A 40% Potential Upside For Investors - DirectorsTalk Interviews
RT-PCR Market key players 2025-2031 : Abbott, Qiagen, GE - openPR.com
Agilent, Danaher could be potential buyers of Qiagenanalyst - MSN
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - MSN
Is Qiagen’s (QGEN) New Infection and Oncology Tools Quietly Rewiring Its Diagnostics Moat? - simplywall.st
Q3 2025 Qiagen NV Earnings Call Transcript - GuruFocus
Brown AdvisoryWMC Strategic European Equity Fund's Qiagen NV(XTER:QIA) Holding History - GuruFocus
QIAGEN NV Hits New 52-Week Low at USD 37.44 Amid Declining Performance - Markets Mojo
Qiagen NV (QGEN) Shares Fall 5.0% -- What GF Score of 79 Tells I - GuruFocus
Qiagen (NYSE:QGEN) Reaches New 52-Week LowHere's Why - MarketBeat
Qiagen NV (QGEN) Stock Price, Trades & News - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Sells 559,616 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough to unlock new upsi - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside? - AD HOC NEWS
Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44 - 富途牛牛
Qiagen N.V. stock (NL0012169213): Is its diagnostics dominance strong enough to unlock new upside? - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more for U.S. inves - AD HOC NEWS
Qiagen N.V. (QGEN) Stock Analysis: Unlocking a 30% Upside Potential in the Diagnostics & Research Sector - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): Why does its genomics leadership matter more for U.S. investors no - AD HOC NEWS
Assessing Qiagen (NYSE:QGEN) Valuation After New Diagnostics Launches And Oncology Workflow Expansion - Sahm
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough for growth i - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics edge strong enough for steady growth? - AD HOC NEWS
Is Qiagen (QGEN) stock considered a safe play (+0.68%) 2026-04-18ATR Levels - Cổng thông tin điện tử Tỉnh Sơn La
Qiagen (NYSE:QGEN) Valuation Check After Recent Share Price Swings - Yahoo Finance
Qiagen N.V. stock (NL0012169213): Is its molecular diagnostics leadership strong enough to unlock ne - AD HOC NEWS
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen Expands Diagnostic Portfolio Amid Renewed Takeover Interest - HarianBasis.co
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 - BioSpace
QIAGEN Showcases AI-Driven Oncology Innovations at AACR 2026 - World Business Outlook
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.22%
0.34%
자본화:
|
볼륨(24시간):